Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

J. P. Hammerstad; W. R. Woodward; J. G. Nutt; S. T. Gancher; G. A. Block; G. Cyhan

doi:10.1097/00002826-199410000-00005

Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

J. P. Hammerstad, W. R. Woodward, J. G. Nutt, S. T. Gancher, G. A. Block, G. Cyhan

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

Original language	English (US)
Pages (from-to)	429-434
Number of pages	6
Journal	Clinical neuropharmacology
Volume	17
Issue number	5
DOIs	https://doi.org/10.1097/00002826-199410000-00005
State	Published - 1994

Keywords

Controlled release levodopa/carbidopa (Sinemet CR) 25/100
Levodopa
Parkinson's disease
Pharmacokinetics

ASJC Scopus subject areas

Pharmacology
Clinical Neurology
Pharmacology (medical)

Access to Document

10.1097/00002826-199410000-00005

Cite this

@article{d86fd4b077d54086a18155fa3b2f8c84,

title = "Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients",

abstract = "The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.",

keywords = "Controlled release levodopa/carbidopa (Sinemet CR) 25/100, Levodopa, Parkinson's disease, Pharmacokinetics",

author = "Hammerstad, {J. P.} and Woodward, {W. R.} and Nutt, {J. G.} and Gancher, {S. T.} and Block, {G. A.} and G. Cyhan",

year = "1994",

doi = "10.1097/00002826-199410000-00005",

language = "English (US)",

volume = "17",

pages = "429--434",

journal = "Clinical neuropharmacology",

issn = "0362-5664",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100)

T2 - Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

AU - Hammerstad, J. P.

AU - Woodward, W. R.

AU - Nutt, J. G.

AU - Gancher, S. T.

AU - Block, G. A.

AU - Cyhan, G.

PY - 1994

Y1 - 1994

N2 - The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

AB - The pharmacokinetics of the clinically determined optimal dose of controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100) after 12 weeks of therapy was studied in nine parkinsonian patients without prior exposure to levodopa. The pharmacokinetics of single oral doses of controlled release levodopa/carbidopa 25/100 and 50/200 were also compared. As predicted from the plasma half-life (1.7 ± 0.3 h) and confirmed by morning trough levels, levodopa did not accumulate when controlled released levodopa/carbidopa 25/100 was administered twice daily. The absorption and bioavailability of CR 25/100 are minimally greater than CR 50/200. Controlled released levodopa/carbidopa 25/100 levodopa plasma levels peak slightly faster than controlled release levodopa/carbidopa 50/200.

KW - Controlled release levodopa/carbidopa (Sinemet CR) 25/100

KW - Levodopa

KW - Parkinson's disease

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0028085949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028085949&partnerID=8YFLogxK

U2 - 10.1097/00002826-199410000-00005

DO - 10.1097/00002826-199410000-00005

M3 - Article

C2 - 9316692

AN - SCOPUS:0028085949

SN - 0362-5664

VL - 17

SP - 429

EP - 434

JO - Clinical neuropharmacology

JF - Clinical neuropharmacology

IS - 5

ER -

Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): Pharmacokinetics and clinical efficacy in untreated parkinsonian patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this